2719-LB: Oral NLRP3 Inhibitor BGE-102 Preserves Retinal Vascular Integrity in a Preclinical Model of Diabetic Retinopathy
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2719-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von AIDEN EBLIMIT und 17 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Introduction and Objective: Diabetic retinopathy (DR) is a leading cause of vision loss, but treatment relies largely on intravitreal therapies, resulting in suboptimal real-world outcomes. Hyperglycemia-driven NLRP3 inflammasome activation contributes to retinal vascular leakage, suggesting that oral NLRP3 inhibition could address this unmet need. We evaluated whether BGE-102, an oral, brain-penetrant NLRP3 inhibitor with therapeutic retinal exposure, could preserve retinal vascular integrity in a streptozotocin (STZ)-induced DR model.
Methods
Male C57BL/6 mice received STZ (65 mg/kg IP × 5 days). Eleven days later, mice were randomized to vehicle, BGE-102 20 mg/kg, or BGE-102 50 mg/kg (PO QD; n=16-20/group) for 96 days alongside healthy controls. Retinal vascular permeability was assessed by fluorescein angiography (FA). Blood-retinal barrier integrity was evaluated by Claudin-5 immunohistochemistry (IHC). Fasting glucose and A1c were monitored. Data were analyzed by one-way ANOVA with Dunnett’s test.
Results
All STZ groups developed sustained hyperglycemia (glucose ~300 mg/dL; A1c >8%) unaffected by BGE-102 at either dose. Despite persistent hyperglycemia, BGE-102 dose-dependently reduced retinal vascular permeability vs vehicle by 74% at 20 mg/kg and 98.7% at 50 mg/kg (both p<0.0001), with the higher dose restoring FA signal to healthy control levels. Claudin-5 IHC showed STZ reduced endothelial vascular content by 46% (p<0.01). BGE-102 restored tight junction integrity at both doses to 95% and 97% of healthy control levels (both p<0.01 vs vehicle).
Conclusion
Oral BGE-102 preserved retinal vascular integrity and restored endothelial tight junctions in a DR model, with efficacy independent of glycemic control. These findings support NLRP3 inhibition as a novel approach to DR and the planned Phase 1b/2a trial in diabetic macular edema. Disclosure A. Eblimit: Employee; Current; BioAge Labs. D. Punzalan: Employee; Current; BioAge Labs. S. Yan: Employee; Current; BioAge LAbs. A. Banicki: Employee; Current; BioAge LAbs. Y. Wang: Employee; Current; BioAge Labs. K. Wilhelmsen: Employee; Current; BioAge Labs. C. Portillo: Employee; Current; BioAge Labs. M. Banicki: Employee; Current; BioAge Labs. M. Cochran: Employee; Current; BioAge Labs. C. Rodriguez: Employee; Current; BioAge Labs. G. Hartman: Employee; Current; BioAge Labs. C. Patil: Employee; Current; BioAge Labs. J. Rebo: Employee; Current; BioAge Labs. R. Hughes: Employee; Current; BioAge Labs. R. Montgomery: Employee; Current; BioAge Labs. E. Morgen: Employee; Current; BioAge Labs. Board Member; Current; BioAge Labs. Stock/Shareholder; Current; BioAge Labs. K. Fortney: Board Member; Current; BioAge Labs. Employee; Current; BioAge Labs. Stock/Shareholder; Current; BioAge Labs. P. Rubin: Employee; Current; BioAge Labs.
Zitieren
APA
EBLIMIT, A., PUNZALAN, D., YAN, S., BANICKI, A., WANG, Y., WILHELMSEN, K., PORTILLO, C., BANICKI, M., COCHRAN, M., RODRIGUEZ, C., HARTMAN, G., PATIL, C., REBO, J., HUGHES, R., MONTGOMERY, R., MORGEN, E., FORTNEY, K., & RUBIN, P. (2026). 2719-LB: Oral NLRP3 Inhibitor BGE-102 Preserves Retinal Vascular Integrity in a Preclinical Model of Diabetic Retinopathy. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2719-lb
Vancouver
EBLIMIT A, PUNZALAN D, YAN S, BANICKI A, WANG Y, WILHELMSEN K, et al. 2719-LB: Oral NLRP3 Inhibitor BGE-102 Preserves Retinal Vascular Integrity in a Preclinical Model of Diabetic Retinopathy. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2719-lb
BibTeX
@article{EBLIMIT2026,
author = {EBLIMIT, AIDEN and PUNZALAN, DEAN and YAN, SHIJUN and BANICKI, ANDREW and WANG, YAN and WILHELMSEN, KEVIN and PORTILLO, CLAUDIA and BANICKI, MATTHEW and COCHRAN, MARY and RODRIGUEZ, CARL and HARTMAN, GEORGE and PATIL, CHRISTOPHER and REBO, JUSTIN and HUGHES, ROBERT and MONTGOMERY, RUSTY and MORGEN, ERIC and FORTNEY, KRISTEN and RUBIN, PAUL},
title = {2719-LB: Oral NLRP3 Inhibitor BGE-102 Preserves Retinal Vascular Integrity in a Preclinical Model of Diabetic Retinopathy},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2719-lb}
}
EUVIMED